CeriBell EEG (CBLL): Rasio rega marang pendapatan
CeriBell, Inc. maintains sufficient liquidity by leveraging operational cash flow from the implementation of neural networks. High pricing power within intensive care units is driven by the critical nature of rapid seizure diagnostics. The estimated P/S ratio reflects the dynamics of this demand, where 9.40 determines the current value of the metric. The growth in capitalization for CeriBell, Inc. is stimulated by the expansion of insurance coverage, sales of consumables, and the expansion of AI brain monitoring across US clinics.
Rincian analitis perusahaan CeriBell Corp (CBLL)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Rasio Utang marang Ekuitas CeriBell, Inc.|CBLL - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas CeriBell EEG|CBLL - Gunggung utang perusahaan|Utang-utang marang aset resik CeriBell Corp|CBLL - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CeriBell|Likuiditas cepet ceribell.com
- informasi bathi lan kelipatan valuasi:
CBLL - Bathi resik perusahaan|Bathi sing dikarepake CeriBell, Inc.|CBLL - Rasio rega marang bathi|Rega marang bathi mangsa ngarep CeriBell Inc|CBLL - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan CeriBell Corp|CBLL - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan CeriBell|CBLL - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ceribell.com|CBLL - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep CeriBell, Inc.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:CBLL, ceribell.com
To assess the financial stability of CeriBell, Inc. (CBLL), it is essential to compare the business's market value with its actual cash flow from AI brain diagnostics. By analyzing the company's P/S ratio, which stands at 9.40, an investor can see the ratio of market capitalization to annual revenue, making it possible to determine the degree of stock overvaluation relative to the adoption rate of innovative EEG headbands in intensive care units and overall sales scaling.
Perusahaan pesaing
Rasio rega marang pendapatan BIIB (biogen.com)|Rasio rega marang pendapatan Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd - Rasio rega marang pendapatan|AXSM: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Corp)|XENE: Multiplikator P/S|VKTX - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Supernus|Rasio kapitalisasi marang pendapatan CPRX (Catalyst Pharma)|Multiplikator P/S DNLI|Kapitalisasi marang pendapatan Harmony Corp HRMY|Biohaven Ltd. - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Multiplikator P/S|Praxis Precision Medicines Inc (PRAX) - Kapitalisasi marang pendapatan|AVXL: Multiplikator P/S|PRTA (Prothena Corp) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Alector Inc.|Rasio rega marang pendapatan ANNX|Rasio rega marang pendapatan Omeros Corporation (OMER)|Rasio rega marang pendapatan NGNE (Neurogene Inc)|Rasio rega marang pendapatan AC Immune Corp ACIU|VYGR: Rasio kapitalisasi marang pendapatan|Neumora Therapeutics - Multiplikator P/S|Rega marang dodolan scilexholding.com|TVGN (Tevogen Bio) - Kapitalisasi marang pendapatan|Alpha Cognition Inc. (ACOG) - Multiplikator P/S|Rasio rega marang pendapatan Cognition Therapeutics, Inc.|IKT: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Cassava Sciences, Inc. (SAVA)|ASRT - Rega marang dodolan|Multiplikator P/S COYA (Coya Therapeutics)|VTGN - Kapitalisasi marang pendapatan|Ovid Rx - Multiplikator P/S|Rega marang dodolan Acumen Pharmaceuticals, Inc|CervoMed Inc. (CRVO) - Rasio rega marang pendapatan|Alterity Therapeutics Limited - Rasio kapitalisasi pasar marang pendapatan|CLNN (Clene Inc) - Multiplikator P/S|PepGen Corp (PEPG) - Koefisien rega marang pendapatan|Multiplikator P/S JUNS|Rasio rega marang pendapatan RLMD (Relmada Corp)|Multiplikator P/S ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Rega marang dodolan|AIFF - Rasio rega marang pendapatan|KLTO: Rasio rega marang pendapatan|neurosense-tx.com (NRSN) - Rasio rega marang pendapatan|RVPH (Reviva Pharmaceuticals, Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan MTVA|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|Koefisien rega marang pendapatan passagebio.com|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|NERV: Rasio kapitalisasi marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|addextherapeutics.com (ADXN) - Kapitalisasi marang pendapatan|ALZN (alzamend.com) - Kapitalisasi marang pendapatan|CYCN - Koefisien rega marang pendapatan|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Pasithea (KTTA)|Multiplikator P/S CRGT|Rasio rega marang pendapatan ATXI (avenuetx.com)|Rasio rega marang pendapatan BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. - Rasio rega marang pendapatan|CHRO - Rasio rega marang pendapatan|ELYM: Rasio rega marang pendapatan|intracellulartherapies.com (ITCI) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|Rega marang dodolan NKGen Biotech Inc NKGN|Kapitalisasi marang pendapatan NRBO (NeuroBo)|Multiplikator P/S Sage Therapeutics Inc (SAGE)|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|Rasio kapitalisasi pasar marang pendapatan TRVN|VIGL - Rasio rega marang pendapatan|Rega marang dodolan anewmeds.com|CERE: Multiplikator P/S
